Truist Securities Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $505

Benzinga Newsdesk www.benzinga.com Negative 60.2%

Neg 60.2% Neu 0% Pos 0%

Truist Securities analyst Danielle Brill maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $515 to $505.